HI SCR47

Urges Hawaii's congressional delegation to monitor The Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration (Case No. 2:22-cv-00223-Z) pending before the U.S. District Court for the Northern District of Texas.

Expresses concern that a ruling in the case could effectively ban mifepristone nationwide and prevent healthcare providers from prescribing it even in states where abortion is legal.

Notes that mifepristone was FDA-approved on September 28, 2000, for medical termination of pregnancy through seven weeks gestation (extended to ten weeks in 2016) and is considered safe and effective.

Calls on Hawaii's congressional delegation to take action to limit the case from further restricting access to safe abortion options and medication abortion.

Directs that certified copies of the resolution be transmitted to members of Hawaii's congressional delegation.